NBIX(Neurocrine Biosciences, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| 毛利润 | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B |
| 营业利润 | $102.50M | $249.00M | $250.90M | $570.50M | $619.10M |
| 净利润 | $89.60M | $154.50M | $249.70M | $341.30M | $478.60M |
| 经营现金流 | $256.50M | $339.40M | $389.90M | $595.40M | $782.70M |
| 自由现金流 | $233.10M | $322.90M | $361.60M | $557.20M | $748.70M |
| 摊薄每股收益 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |